Target Name: GOLM2
NCBI ID: G113201
Review Report on GOLM2 Target / Biomarker Content of Review Report on GOLM2 Target / Biomarker
GOLM2
Other Name(s): cancer susceptibility candidate 4 | Cancer susceptibility candidate 4 | Golgi membrane protein 2, transcript variant 1 | Golgi membrane protein 2 | protein CASC4 | Protein GOLM2 (isoform a) | GOLM2_HUMAN | cancer susceptibility candidate gene 4 protein | CASC4 | H63 | GOLM2 variant 1 | cancer susceptibility 4 | golgi membrane protein 2 | gene associated with HER-2/neu overexpression | Protein GOLM2 | DKFZp459F1927 | MGC74708 | Cancer susceptibility candidate gene 4 protein | Gene associated with HER-2/neu overexpression

GOLM2: A Cancer Susceptibility Candidate and Potential Drug Target

Golm2 (Golm2-associated gene 2) is a non-coding RNA molecule that has been identified as a potential cancer susceptibility candidate and drug target in various studies. Golm2 is a key regulator of cell proliferation and has been shown to play a role in the development and progression of various diseases, including cancer. In this article, we will discuss the biology of Golm2, its potential as a cancer drug target, and its current status in the scientific community.

The Golm2 gene is located on chromosome 1p36 and has been shown to encode a protein that is involved in the regulation of cell cycle progression. Golm2 has been shown to play a role in the regulation of cell proliferation, cell adhesion, and the transformation of normal cells into cancer cells.

Golm2 has also been shown to be involved in the regulation of apoptosis, which is the process by which cells die naturally. Studies have shown that Golm2 can induce apoptosis in cancer cells and that inhibition of Golm2 has been shown to increase the sensitivity of cancer cells to chemotherapy.

In addition to its role in cell cycle and apoptosis, Golm2 has also been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels form in the body. Studies have shown that Golm2 can promote the formation of new blood vessels in cancer cells, which can lead to the development of new tumors.

Golm2 has also been shown to be involved in the regulation of inflammation, which is a critical part of the immune system. Studies have shown that Golm2 can contribute to the regulation of inflammation in cancer cells, which can contribute to the development and progression of cancer.

In addition to its role in cancer development, Golm2 has also been shown to be involved in the regulation of stem cell maintenance. Studies have shown that Golm2 can contribute to the regulation of stem cell self-renewal and that inhibition of Golm2 has been shown to increase the number of stem cells in the body.

Golm2 has also been shown to be involved in the regulation of tissue repair, which is a critical part of the immune system. Studies have shown that Golm2 can contribute to the regulation of tissue repair in cancer cells, which can contribute to the development and progression of cancer.

In conclusion, Golm2 is a non-coding RNA molecule that has been shown to play a role in the regulation of cell cycle progression, apoptosis, angiogenesis, inflammation, stem cell maintenance, and tissue repair. These studies suggest that Golm2 may be a valuable drug target for the treatment of various diseases, including cancer. Further research is needed to fully understand the biology of Golm2 and its potential as a drug target.

Protein Name: Golgi Membrane Protein 2

The "GOLM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GOLM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GOLPH3 | GOLPH3L | GOLT1A | GOLT1B | GON4L | GON7 | GOPC | GORAB | GORASP1 | GORASP2 | GOSR1 | GOSR2 | GOT1 | GOT1-DT | GOT1L1 | GOT2 | GOT2P1 | GP1BA | GP1BB | GP2 | GP5 | GP6 | GP9 | GPA33 | GPAA1 | GPALPP1 | GPAM | GPANK1 | GPAT2 | GPAT3 | GPAT4 | GPATCH1 | GPATCH11 | GPATCH2 | GPATCH2L | GPATCH3 | GPATCH4 | GPATCH8 | GPBAR1 | GPBP1 | GPBP1L1 | GPC1 | GPC1-AS1 | GPC2 | GPC3 | GPC4 | GPC5 | GPC5-AS1 | GPC5-AS2 | GPC6 | GPC6-AS1 | GPC6-AS2 | GPCPD1 | GPD1 | GPD1L | GPD2 | GPER1 | GPHA2 | GPHB5 | GPHN | GPI | GPI transamidase complex | GPI-GlcNAc transferase complex | GPIHBP1 | GPKOW | GPLD1 | GPM6A | GPM6B | GPN1 | GPN2 | GPN3 | GPNMB | GPR101 | GPR107 | GPR108 | GPR119 | GPR12 | GPR132 | GPR135 | GPR137 | GPR137B | GPR137C | GPR139 | GPR141 | GPR142 | GPR143 | GPR146 | GPR148 | GPR149 | GPR15 | GPR150 | GPR151 | GPR152 | GPR153 | GPR155 | GPR156 | GPR157 | GPR158 | GPR158-AS1 | GPR15LG